Key Takeaway
Retatrutide telehealth in Missouri, will be available through FormBlends as soon as this medication receives FDA approval. As a growing city with a...
Retatrutide telehealth in Missouri, will be available through FormBlends as soon as this medication receives FDA approval. As a growing city with a metro population of roughly , Missouri residents deserve early access to what researchers are calling the most powerful weight loss medication ever studied. We're preparing to offer retatrutide through our telehealth platform the moment it becomes available.
What Is Retatrutide?
Retatrutide is a triple-action hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors simultaneously . This three-pronged approach sets it apart from current medications like semaglutide (which targets GLP-1 alone) and tirzepatide (which targets GIP and GLP-1). By adding glucagon receptor activation, retatrutide increases energy expenditure directly, importantly telling your body to burn more calories even at rest.
In Phase 2 clinical trials, participants taking the highest dose of retatrutide lost an average of 24.2% of their body weight over 48 weeks[1] . Some participants lost over 30%. Those numbers surpass anything seen with currently available GLP-1 medications.
Why Missouri Residents Should Plan Ahead
Demand for retatrutide is expected to be enormous once it launches. Missouri is home to roughly people, and obesity rates across mean a significant portion of the population could benefit from this medication. By signing up for the FormBlends waitlist now, you can:
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
- Be among the first Missouri patients to access retatrutide when it launches
- Complete your medical evaluation in advance so treatment can begin immediately
- Start with a current GLP-1 medication now and transition to retatrutide when available
- Get answers to your questions from a licensed physician before the rush begins
How Retatrutide Compares to Current Options
| Medication | Receptors Targeted | Avg Weight Loss | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | ~15-17% | FDA approved |
| Tirzepatide (Zepbound) | GIP + GLP-1 | ~20-22% | FDA approved |
| Retatrutide | GIP + GLP-1 + Glucagon | ~24% (Phase 2) | In clinical trials |
What to Do While You Wait in Missouri
Retatrutide is still in Phase 3 clinical trials and doesn't yet have an FDA approval date. In the meantime, Missouri residents have effective options available right now through FormBlends:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →- Compounded semaglutide for affordable GLP-1 weight loss therapy
- Compounded tirzepatide for dual-action GIP/GLP-1 treatment
- Peptide therapy for recovery, wellness, and body composition support
Starting treatment now means you can build healthy habits, begin losing weight, and be in a strong position to transition to retatrutide if your physician recommends it after launch.
Frequently Asked Questions
When will retatrutide be available in Missouri?
Retatrutide is currently in Phase 3 clinical trials. If approved, it could be available as early as late 2025 or 2026, though timelines can shift . FormBlends will offer it through telehealth to Missouri patients as soon as it receives FDA approval.
Can I start a different medication now and switch to retatrutide later?
Yes. Many patients begin with semaglutide or tirzepatide and plan to discuss a transition with their physician once retatrutide launches. Your FormBlends provider can help you create a plan that makes sense for your goals.
Will FormBlends offer compounded retatrutide?
Compounding availability will depend on patent status and regulatory factors at the time of launch. We will keep our Missouri patients informed as the field develops.
How do I join the waitlist?
Complete your free online evaluation at FormBlends. Our team will keep you updated on retatrutide availability and can start you on an existing treatment if you want to begin losing weight now.
Medical References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Get Ready for Retatrutide in Missouri
If you're near the downtown area or anywhere in the Missouri metro area, FormBlends will bring retatrutide directly to you through telehealth the moment it becomes available. Don't wait for launch day to start your weight loss process. Complete your online evaluation today and explore your options with a licensed physician.